eptifibatide

Eptifibatide is a synthetic cyclic heptapeptide that acts as a reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, an integrin found on the surface of platelets. By binding to this receptor, eptifibatide prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands, thereby inhibiting the final common pathway of platelet aggregation. It was originally developed by COR Therapeutics and Millennium Pharmaceuticals (now part of Takeda) and is marketed under the brand name Integrilin. The drug is primarily indicated for the treatment of acute coronary syndrome (ACS), including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), and for patients undergoing percutaneous coronary intervention (PCI). Clinical research has also explored its utility in reducing vaso-occlusive crises in sickle cell disease and as an adjunctive treatment in acute ischemic stroke and severe sepsis.

Brand names

Integrilin

Other names

依替巴肽